Clinical Effect and Nursing Strategy of Panimab in the Treatment of K-ras Wild Type Metastatic Colorectal Cancer

  • Lina Bian
Keywords: Parnidumab, Epidermal growth factor; Colorectal cancer; Drug therapy

Abstract

In this paper, we compared the efficacy of panimib and cetuximab combined with irinotecan in the treatment of KRAS wild-type metastatic colorectal cancer. Thirty-five patients with KRAS wild-type metastatic colorectal cancer were divided into two groups by random number table method. The two groups were treated with epidermal growth factor receptor inhibitor parnidumab (20 cases) and cetuximab combined with irinotecan (15 cases). The difference between the two groups was statistically analyzed. The results showed that 24.0% and 28% of the patients in panimimab group and cetuximab combined with irinotecan group had partial remission respectively; the median overall survival time of the two groups was 8 months and 8.5 months respectively, with no significant difference; the incidence of adverse reactions in the two groups was 91% and 95%, respectively. Conclusion: paniximab and cetuximab combined with irinotecan have similar therapeutic effect on patients with KRAS wild-type metastatic colorectal cancer, and can be used as the third-line therapeutic drugs for patients with chemotherapy resistance to colorectal cancer in clinical application.

Published
2020-03-01